TOBIN JAMES R sold $3.1M of GMED

TOBIN JAMES R sold 41,666 shares of GLOBUS MEDICAL INC (GMED) at an average of $75.16 ($75.10–$75.68, $3.13M total) across 2 trades on 2026-11-10.

Original reporting
SEC EDGAR · TOBIN JAMES R
Published Nov 12, 2026, 11:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 11:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GMED
Bearish
medium confidence
Mentioned
$GMED
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GMEDBearishLow
01

Why it matters

The filing provides fresh data on insider sentiment, which may influence short‑term trading decisions.

02

Market read

The insider sale introduces a modest bearish signal for GMED, but limited broader market effect.

03

What to watch

Potential tax‑loss harvesting or personal liquidity needs of the director.

Relevance 6/10Novelty 4/10Timing: post‑market filing on 2026‑11‑12

Background

Form 4 filings disclose insider transactions; a director selling all holdings is noteworthy but not uncommon.

Company-level read

Ticker impact

$GMEDBearishMedium confidence
Context

Director Tobin James R sold all 41,666 shares for $3.13M in an open‑market Form 4 filing.

Expected impact

likely downward pressure as investors price in the insider sell

Evidence & confidence

A director off‑boarding with a full divestiture is a material insider action, though the dollar amount is modest for a listed company.

Market effects

Minimal impact on the broader medical device sector.

Limited to U.S. investors tracking insider activity.

None

Counterpoint

The sale could be unrelated to company fundamentals and merely portfolio rebalancing.

Key entities

  • Tobin James R

    Director of Globus Medical Inc.

  • Globus Medical Inc.

    Medical device manufacturer listed on NASDAQ.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GMEDHighAI 8/10

Why Globus Medical (GMED) shares are plunging today

Globus Medical (GMED) shares fell 11.6% after reporting Q3 2026 revenue of $763.7M, below estimates, and lowering full-year revenue guidance to $3.09B. Adjusted EPS of $1.23 beat estimates. The company cited product launch delays and revenue recovery issues. The board authorized a $500M share repurchase program.

$GMEDHighAI 8/10

Globus Medical Inc (GMED) Q3 2026 Earnings Call Highlights: Revenue Miss, Nevro Weakness

Globus Medical (GMED) reported Q3 2026 revenue of $763.7M, missing expectations and lowering full-year guidance to $3.09B. Nevro revenue declined 25.7% YoY, and US Spine growth slowed. Despite this, free cash flow reached a record $225M, and gross margins expanded to 69.5%. The company expects 2027 growth from new products and market expansion, with mid- to high-single-digit revenue growth targeted.

$GMEDMedAI 8/10

Globus Medical Q3 Earnings Call Highlights

Globus Medical (GMED) reported Q3 earnings with GAAP net income of $141.2M and adjusted net income of $167M. The company expects a mid-single-digit revenue decline in Q4 due to delayed product launches and slower recovery at Nevro. Nevro's revenue fell 9% sequentially, but adjusted EBITDA margin improved to 19.9%. Globus plans to launch a new implantable pulse generator in 2027 and completed two small acquisitions. Operating cash flow rose 6% to $265M, and free cash flow increased 5% to $225M.

$GMEDHigh

Why Globus Medical (GMED) shares are plunging today

Globus Medical (GMED) shares fell 11.6% after Q3 2026 revenue of $763.7M missed estimates and full-year guidance was lowered to $3.09B. Adjusted EPS of $1.23 beat estimates. The company cited product launch delays and revenue recovery issues. The board authorized a $500M share repurchase program. The stock is down 17.7% YTD.

$GMEDHighAI 8/10

Why is Globus Medical stock plunging today?

Globus Medical (GMED) stock fell 12.5% to $71.26, a 52-week low, after Q3 2026 revenue missed estimates at $763.7M, down 0.7% YoY. The company cut full-year revenue guidance to $3.09B. Analysts downgraded the stock, citing weak growth outlook and insider selling. The S&P 500 and Nasdaq rose, but GMED underperformed.